Lund, Sweden, September 17, 2009 - Active Biotech (NASDAQ OMX Nordic: ACTI) is scheduled to present at the UBS Global Life Sciences Conference held September 21-23, 2009 at the Grand Hyatt, Grand Central in New York City, US. During the presentation, an update regarding Active Biotech's development programs will be provided. The presentation will include the Phase III projects laquinimod, a novel oral immunomodulatory drug for the treatment of multiple sclerosis, which is licensed to Teva Pharmaceutical Industries Ltd and ANYARA, Active Biotech's novel concept for tumor therapy in a Phase III study for renal cell cancer. Also, the prostate cancer project TASQ, the SLE project 57-57 and the pre-clinical ISI project will be presented. The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site. To access the live and replay presentations please go to - www.activebiotech.com. The presentation will take place on September 22, at 2:00 pm US Eastern Time / 20:00 Central European Time. About Active Biotech Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily of renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please visit www.activebiotech.com for more information. Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 2:00 pm CET on September 17, 2009. Contacts: Active Biotech AB Göran Forsberg, VP Investor Relations & Business Development P.O. Box 724, SE-220 07 Lund, Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00